Targeting cytokine signaling in autoimmunity: back to the future and beyond. (December 2016)
- Record Type:
- Journal Article
- Title:
- Targeting cytokine signaling in autoimmunity: back to the future and beyond. (December 2016)
- Main Title:
- Targeting cytokine signaling in autoimmunity: back to the future and beyond
- Authors:
- Hirahara, Kiyoshi
Schwartz, Daniella
Gadina, Massimo
Kanno, Yuka
O'Shea, John J - Abstract:
- Highlights: Targeting JAK–STAT signaling pathway is effective in the treatment of autoimmune diseases. Unlike biologics, Jakinibs block a range of cytokines but their effect can be 'dialed' up or down. Identifying genomic regulatory regions provides clues to targeting signaling pathways. Abstract : Cytokines represent structurally diverse soluble factors with critical roles in normal immune function and the pathogenesis of autoimmunity. The emergence of many successful biological therapies targeting cytokines and cytokine receptors exemplifies the importance of cytokines in driving human autoimmune disease; unsurprisingly, there is no paucity of reviews on this subject. Nonetheless, many patients with autoimmune disease do not respond to biologicals, and cure remains an unmet goal. Thus, targeting the intracellular pathways employed by cytokines provides new therapeutic opportunities. A subset of cytokines utilizes the Janus kinase-signal transducer of activators of transcription (JAK–STAT) pathway as a mode of signal transduction. First generation JAK inhibitors (jakinibs) are used to treat rheumatologic disease, and second-generation jakinibs are being developed. Simultaneously, rapid advances are being made in our understanding of the genomic and epigenomic impact of cytokines. In this review, we will briefly review the role of JAK–STAT-dependent cytokines in immune-mediated disease, the current status of Jakinibs, and future possibilities for therapeutic interventionHighlights: Targeting JAK–STAT signaling pathway is effective in the treatment of autoimmune diseases. Unlike biologics, Jakinibs block a range of cytokines but their effect can be 'dialed' up or down. Identifying genomic regulatory regions provides clues to targeting signaling pathways. Abstract : Cytokines represent structurally diverse soluble factors with critical roles in normal immune function and the pathogenesis of autoimmunity. The emergence of many successful biological therapies targeting cytokines and cytokine receptors exemplifies the importance of cytokines in driving human autoimmune disease; unsurprisingly, there is no paucity of reviews on this subject. Nonetheless, many patients with autoimmune disease do not respond to biologicals, and cure remains an unmet goal. Thus, targeting the intracellular pathways employed by cytokines provides new therapeutic opportunities. A subset of cytokines utilizes the Janus kinase-signal transducer of activators of transcription (JAK–STAT) pathway as a mode of signal transduction. First generation JAK inhibitors (jakinibs) are used to treat rheumatologic disease, and second-generation jakinibs are being developed. Simultaneously, rapid advances are being made in our understanding of the genomic and epigenomic impact of cytokines. In this review, we will briefly review the role of JAK–STAT-dependent cytokines in immune-mediated disease, the current status of Jakinibs, and future possibilities for therapeutic intervention using genomic insights. … (more)
- Is Part Of:
- Current opinion in immunology. Volume 43(2016)
- Journal:
- Current opinion in immunology
- Issue:
- Volume 43(2016)
- Issue Display:
- Volume 43, Issue 2016 (2016)
- Year:
- 2016
- Volume:
- 43
- Issue:
- 2016
- Issue Sort Value:
- 2016-0043-2016-0000
- Page Start:
- 89
- Page End:
- 97
- Publication Date:
- 2016-12
- Subjects:
- Immunology -- Periodicals
Allergy -- Periodicals
Immunology -- Abstracts -- Periodicals
Allergy -- Abstracts -- Periodicals
616.079 - Journal URLs:
- http://www.sciencedirect.com/science/journal/09527915 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.coi.2016.10.001 ↗
- Languages:
- English
- ISSNs:
- 0952-7915
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3500.775300
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 2434.xml